Impax Laboratories, Inc. (IPXL) EPS Estimated At $0.17 as of May, 9

April 17, 2018 - By Benjamin Allen

Impax Laboratories, Inc. (NASDAQ:IPXL) Corporate Logo
Big Money Sentiment decreased to 1.26 in Q4 2017. It has change of 0.49, from 2017Q3’s 1.75. The ratio fall due to Impax Laboratories, Inc. positioning: 27 sold and 45 reduced. 36 funds amassed stakes and 55 increased stakes. Investors holded 65.84 million in 2017Q3 but now own 73.13 million shares or 11.06% more.
Tci Wealth Advisors holds 59 shs. 50,099 were accumulated by Texas Permanent School Fund. Glenmede Tru Na reported 0% stake. Fosun Intll Ltd reported 3.85M shs. Jefferies Group Limited reported 14,881 shs. The Australia-based Macquarie Group Ltd has invested 0% in Impax Laboratories, Inc. (NASDAQ:IPXL). Suntrust Banks reported 0.01% stake. Moreover, Teachers Retirement Systems Of The State Of Kentucky has 0.01% invested in Impax Laboratories, Inc. (NASDAQ:IPXL) for 69,373 shs. Bluecrest Mgmt Ltd holds 0.01% or 20,170 shs in its capital. State Of Alaska Department Of Revenue accumulated 14,798 shs. California Employees Retirement Sys stated it has 127,428 shs or 0% of all its holdings. Thrivent For Lutherans reported 46,201 shs. Susquehanna Gp Llp has 0% invested in Impax Laboratories, Inc. (NASDAQ:IPXL) for 27,834 shs. San Francisco Sentry Invest Group (Ca) holds 0% or 147 shs. Swiss Bank & Trust has 116,900 shs.

Impax Laboratories, Inc. (NASDAQ:IPXL)’s earnings report is expected On May, 9., Faxor reports. Analysts expect change of 54.55 % or $0.06 from previous year’s $0.11 EPS compared to current’s $0.17 EPS. In case of $0.17 EPS IPXL’s profit could hit $12.20 million. Last quarter $0.11 EPS was reported. Analysts sees 54.55 % EPS growth this quarter. IPXL reached $19 on during the last trading session after $0.65 change.Currently Impax Laboratories, Inc. is uptrending after 51.97% change in last April 17, 2017. IPXL has 482,497 shares volume. IPXL outperformed by 40.42% the S&P 500.

Impax Laboratories, Inc. (NASDAQ:IPXL) Ratings Coverage

In total 9 analysts cover Impax Laboratories (NASDAQ:IPXL). “Buy” rating has 3, “Sell” are 1, while 5 are “Hold”. 33% are bullish. 11 are the (NASDAQ:IPXL)’s analyst reports since October 17, 2017 according to StockzIntelligence Inc. The stock rating was maintained by RBC Capital Markets with “Hold” on Friday, March 2. On Friday, November 10 the stock of Impax Laboratories, Inc. (NASDAQ:IPXL) has “Hold” rating given by Cowen & Co. The company rating was maintained by Cantor Fitzgerald on Thursday, November 9. On Tuesday, January 2 Leerink Swann initiated the shares of IPXL in report with “Buy” rating. On Monday, October 30 the firm has “Hold” rating by BMO Capital Markets given. On Tuesday, October 17 the company was maintained by RBC Capital Markets. On Tuesday, December 12 Guggenheim initiated the shares of IPXL in report with “Hold” rating. On Thursday, March 1 Cowen & Co maintained Impax Laboratories, Inc. (NASDAQ:IPXL) with “Hold” rating. In Monday, October 30 report UBS maintained it with “Sell” rating and $16 target. On Tuesday, February 27 the company was maintained by Susquehanna.

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, makes, and markets bioequivalent pharmaceutical products.The company has $1.36 billion market cap. It operates in two divisions, Impax Generics and Impax Specialty Pharma.Currently it has negative earnings. The Impax Generics segment provides generic pharmaceutical products directly to wholesalers, retail drug chains, and others; generic prescription products through third-party pharmaceutical entities pursuant to alliance agreements; generic pharmaceutical over-the-counter and prescription products to third parties; and generic pharmaceutical OTC products through third-party pharmaceutical companies pursuant to alliance agreements.

Impax Laboratories, Inc. (NASDAQ:IPXL) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.